// App-Quantinova.ai

153 : Mature Results From ECOG Study E1405 A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Researchers

Presenter

  • Brad S. Kahl

Principal Investigators

  • Hailun Li

  • Mitchell R Smith

  • Randy D. Gascoyne

  • David T. Yang

  • Elisabeth Paietta

  • Ranjana H. Advani

  • Sandra J. Horning

Medical Centers

  • Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, BC Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

  • Peripheral neuropathy

  • Lymphomas

Biomarkers

  • Granulocyte colony-stimulating factor

  • Lactate dehydrogenase

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Vincristine

  • Doxorubicin

  • Bortezomib

  • Rituximab

  • Filgrastim

Outcome

  • N/A

Study Design

  • randomized

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved